Sign In
Buy FLXN
$25.10
-0.0069 (-0.0275%)
At Close: Jun 22, 2026
Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates
11:05pm, Wednesday, 05'th Aug 2020
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights | MarketScreener
08:02pm, Wednesday, 05'th Aug 2020Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights
08:01pm, Wednesday, 05'th Aug 2020
* Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $15.5 million in second quarter 2020 * Flexion resumed enrollment in Phase 1 dose-esc
Flexion Therapeutics (NASDAQ:FLXN) Downgraded by ValuEngine
06:50am, Sunday, 02'nd Aug 2020
ValuEngine downgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a buy rating to a hold rating in a research note released on Wednesday, ValuEngine reports. FLXN has been the topic of several o
Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020
08:30pm, Thursday, 30'th Jul 2020
BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highligh
Flexion Therapeutics: An Orthopedic Surgeon And Zilretta User Says Short The Stock
02:00pm, Thursday, 30'th Jul 2020
Currently available studies show minimal clinical improvement compared to traditional cortisone based on primary data points.
An Interview With PRO Top Idea Contributor, Carolina Doc, Regarding Flexion Therapeutics
09:00am, Thursday, 30'th Jul 2020
Seeking Alpha PRO has conducted an interview with our recent Top Idea contributor, Carolina Doc, regarding their compelling thesis on Flexion Therapeutics.
Will Flexion Therapeutics (FLXN) Report Negative Q2 Earnings? What You Should Know
04:32pm, Tuesday, 28'th Jul 2020
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OK Boomer, Flexion Stock Is Made For You
10:31am, Friday, 24'th Jul 2020
Flexion Therapeutics (NASDAQ:FLXN) may be one of the best-kept secrets in biotech. The company has a product that addresses a condition that affects a growing number of Americans. But FLXN stock start
Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know
04:00pm, Thursday, 23'rd Jul 2020
Does Flexion Therapeutics (FLXN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Options Traders Betting on a Big Move in Flexion (FLXN) Stock?
01:56pm, Wednesday, 15'th Jul 2020
Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.
Flexion Therapeutics : Announces Preliminary Second-Quarter 2020 ZILRETTA Net Sales | MarketScreener
12:50pm, Wednesday, 15'th Jul 2020Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales | MarketScreener
11:00am, Tuesday, 14'th Jul 2020Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales
10:59am, Tuesday, 14'th Jul 2020
* Company reported ZILRETTA (triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarter * Demand for ZILRETTA from healthcare p
Flexion Therapeutics (FLXN) Upgraded to Buy: What Does It Mean for the Stock?
04:00pm, Wednesday, 08'th Jul 2020
Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
